Evidence map›Paper›PMID 27378687›Full record

ArticleHuman molecular genetics2016

Genetic ablation of IP3 receptor 2 increases cytokines and decreases survival of SOD1G93A mice.

Kim A Staats, Stephanie Humblet-Baron, Andre Bento-Abreu, Wendy Scheveneels, Alexandros Nikolaou, Kato Deckers, Robin Lemmens, An Goris, Jo A Van Ginderachter, Philip Van Damme and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human molecular genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Caffeic Acid Inhibits Degranulation, Cytokine Secretions, andInternational journal of molecular sciences · 2025
    Article
  3. Cysteine reactivity profiling identifies host regulators ofbioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IPInternational journal of molecular sciences · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. IPNeurobiology of disease · 2020
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Kim A StaatsKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
Stephanie Humblet-BaronVIB and Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Andre Bento-AbreuKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
Wendy ScheveneelsKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
Alexandros NikolaouMolecular and Biochemical Pharmacology Laboratory, Vrije Universiteit Brussel.
Kato DeckersCenter for Molecular and Vascular Biology, University of Leuven.
Robin LemmensKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
An GorisKU Leuven - University of Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
Jo A Van GinderachterMyeloid Cell Immunology Laboratory, VIB, Inflammation Research Center.
Philip Van DammeKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
Chihiro HisatsuneLaboratory for Developmental Neurobiology, Brain Science Institute, RIKEN, Wako-shi, Saitama, Japan.
Katsuhiko MikoshibaLaboratory for Developmental Neurobiology, Brain Science Institute, RIKEN, Wako-shi, Saitama, Japan.
Adrian ListonVIB and Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Wim RobberechtKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND).
Ludo Van Den BoschKU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND) ludo.vandenbosch@vib-kuleuven.be.
KU Leuven · BEVIB-KU Leuven Center for Brain & Disease Research · BERIKEN Center for Brain Science · JPVIB-KU Leuven Center for Microbiology · BEVIB-UGent Center for Inflammation Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease characterized by the selective death of motor neurons. Disease pathophysiology is complex and not yet fully understood. Higher gene expression of the inositol 1,4,5-trisphosphate receptor 2 gene (ITPR2), encoding the IP

Indexed as

Amyotrophic Lateral SclerosisAnimalsDisease Models, AnimalHumansInflammationInositol 1,4,5-Trisphosphate ReceptorsInterferon-gammaInterleukin-1betaInterleukin-6LipopolysaccharidesMaleMiceMice, KnockoutMotor NeuronsSpinal CordSuperoxide Dismutase-1IL1B protein, mouseInositol 1,4,5-Trisphosphate ReceptorsInterferon-gammaInterleukin-1betaInterleukin-6Ip3r2 protein, mouseLipopolysaccharidesSod1 protein, mouseSuperoxide Dismutase-1

Identifiers

PMID27378687
PMCPMC5179944
OpenAlexW2472424356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.